• Filing Date: 2021-03-31
  • Form Type: 10-K
  • Description: Annual report
v3.21.1
Business Combination (Tables)
12 Months Ended
Dec. 31, 2020
Business Combinations [Abstract]  
Schedule of Business Acquisition, Pro Forma Information

The following summary, prepared on a proforma basis, combines the consolidated results of operations of the Company with those of Impact Biomedical as if the acquisition took place on January 1, 2019. The pro forma consolidated results include the impact of certain adjustments.

 

    2020 Unaudited     2019 Unaudited  
Sales   $ 17,411,000     $ 15,550,000  
Net income (loss) attributed to common stockholders   $ 1,219,000     $ (3,343,000 )
Basic earnings per share   $ 0.30     $ (2.51 )
Diluted earnings per share   $ 0.11     $ (0.39 )